Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1054)	5/4/2000 11:06:00 AM
From: Biomaven	Read Replies (1) \| Respond to of 52153

A high-profile article about gene therapy for cancer in today's WSJ. Prominent mention of the SGP p53 program and an Aventis/Introgen program I don't know much about. interactive.wsj.com The SGP program of course relies on a license from GZMO: Genzyme Molecular Oncology licensed to Schering-Plough Corporation its rights to the p53 gene, an important tumor suppressor gene implicated in over 50 percent of all cancers. Schering-Plough is now conducting phase II trials of a p53 therapy that if successfully commercialized would provide milestone payments and Genzyme Molecular Oncology's first product revenue through royalties. Peter (from the GENZ web site)